An hypothesis concerning optimal therapy in HIV disease.
Ampligen, a mismatched double stranded RNA, is hypothesized to be an ideal base therapy for HIV disease to which other agents, such as the nucleoside analogue, AZT, can be advantageously added. The unique properties of Ampligen which support this hypothesis include activation of immune cells, inhibition of virus replication by inducing an antiviral cellular state and inhibition of growth of neoplastic cells. Ampligen is synergistic with other agents being used or being tested for use in HIV disease and is without toxicity.
Gillespie
D
D
Department of Neoplastic Diseases, Hahnemann University, Philadelphia, PA 19102.
Carter
W A
WA
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D008954:Models, Biological; D011070:Poly I-C / Q000008:administration & dosage / Q000627:therapeutic use*; D011072:Poly U / Q000008:administration & dosage / Q000627:therapeutic use*; D012330:RNA, Double-Stranded / Q000008:administration & dosage / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D000998:Antiviral Agents; D012330:RNA, Double-Stranded; D011072:Poly U; C047490:poly(I).poly(c12,U); D011070:Poly I-C